{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:30:20Z","timestamp":1762453820589,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jcmgh.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T20:23:50Z","timestamp":1606335830000},"page":"1163-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation"],"prefix":"10.1016","volume":"11","author":[{"given":"Wing-Yiu Jason","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meleri","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.C.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2020.11.012_bib1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/014107680409700504","article-title":"Diagnosis and treatment of hepatitis C","volume":"97","author":"D\u2019Souza","year":"2004","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib3","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"ASTRAL-2 Investigators, ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib4","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.7326\/0003-4819-125-8-199610150-00002","article-title":"Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy\u2014Collaborative Study Group","volume":"125","author":"Zein","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1386-6346(03)00269-9","article-title":"Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection","volume":"27","author":"Miglioresi","year":"2003","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s10620-007-9757-9","article-title":"Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin","volume":"52","author":"Sjogren","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2011.04714.x","article-title":"Systematic review: epidemiology of hepatitis C genotype 6 and its management","volume":"34","author":"Chao","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/MEG.0b013e3283488aba","article-title":"Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse","volume":"23","author":"Shoeb","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver\u2014EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.3835","article-title":"Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus","volume":"49","author":"Ansari","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir","volume":"157","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2014.127","article-title":"Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection","volume":"13","author":"Wong","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/MMBR.00027-06","article-title":"Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action","volume":"70","author":"Garc\u00eda","year":"2006","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.gene.6363984","article-title":"Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR","volume":"4","author":"Knapp","year":"2003","journal-title":"Genes Immun"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.antiviral.2009.05.004","article-title":"Translational insensitivity to potent activation of PKR by HCV IRES RNA","volume":"83","author":"Shimoike","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib21","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1128\/MCB.18.9.5208","article-title":"Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation","volume":"18","author":"Gale","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib22","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1073\/pnas.062055699","article-title":"Regulation of PKR and IRF-1 during hepatitis C virus RNA replication","volume":"99","author":"Pflugheber","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib23","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1128\/JVI.77.7.3898-3912.2003","article-title":"Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication","volume":"77","author":"Wang","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.virol.2019.01.024","article-title":"Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase","volume":"529","author":"Suzuki","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib26","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1073\/pnas.1513341112","article-title":"Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness","volume":"112","author":"Sung","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib27","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1074\/jbc.M113.527796","article-title":"Activation of protein kinase PKR requires dimerization-induced cis-phosphorylation within the activation loop","volume":"289","author":"Dey","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1074-7613(00)00014-5","article-title":"Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection","volume":"13","author":"Balachandran","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/excr.1995.1126","article-title":"Nuclear localization of the interferon-inducible protein kinase PKR in human cells and transfected mouse cells","volume":"218","author":"Jeffrey","year":"1995","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1101\/gad.242644.114","article-title":"PKR is activated by cellular dsRNAs during mitosis and acts as a mitotic regulator","volume":"28","author":"Kim","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41598-018-19683-6","article-title":"Differential effects of SUMO1 and SUMO3 on PKR activation and stability","volume":"8","author":"Maarifi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib32","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/emboj\/20.14.3771","article-title":"The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR","volume":"20","author":"Donz\u00e9","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/excr.1997.3908","article-title":"Ultrastructural localization of interferon-inducible double-stranded RNA-activated enzymes in human cells","volume":"239","author":"Besse","year":"1998","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.emboj.7600049","article-title":"An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer\u2019s disease","volume":"23","author":"Onuki","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib35","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1016\/j.febslet.2007.08.001","article-title":"The double-strand RNA-dependent protein kinase PKR plays a significant role in a sustained ER stress-induced apoptosis","volume":"581","author":"Lee","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52237","article-title":"Hepatitis C virus exploits cyclophilin A to evade PKR","volume":"9","author":"Colpitts","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jcmgh.2020.11.012_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10495-019-01528-w","article-title":"Simultaneous polychromatic flow cytometric detection of multiple forms of regulated cell death","volume":"24","author":"Bergamaschi","year":"2019","journal-title":"Apoptosis"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:26:15Z","timestamp":1762453575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X20301910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["S2352345X20301910"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.11.012","relation":{},"ISSN":["2352-345X"],"issn-type":[{"type":"print","value":"2352-345X"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}